Date: 2013-10-31
Type of information: Services contract
Compound: conformationally selective fragment ligands for an oncology target
Company: Actelion (Switzerland) ZoBio (The Netherlands)
Therapeutic area: Technology - Services - Cancer - Oncology
Type agreement: services
Action mechanism:
Disease:
Details: * On October 31, 2013, ZoBio has announced a collaboration with Actelion Pharmaceuticals Ltd to discover conformationally selective fragment ligands for one of Actelion’s oncology targets. Under the agreement, ZoBio will apply its proprietary TINS technology to screen a library of drug fragments for specific binding to the desired conformation of the target. When successful, ZoBio will use a variety of biophysical methods, including its novel NMR-based structural biology, to validate and provide insight into the binding mechanism of the ligands.
Financial terms:
Latest news:
